| Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic … F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ... Cancer discovery 5 (8), 860-877, 2015 | 780 | 2015 |
| Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial T Cascone, WN William Jr, A Weissferdt, CH Leung, HY Lin, A Pataer, ... Nature medicine 27 (3), 504-514, 2021 | 436 | 2021 |
| The human tumor atlas network: charting tumor transitions across space and time at single-cell resolution O Rozenblatt-Rosen, A Regev, P Oberdoerffer, T Nawy, A Hupalowska, ... Cell 181 (2), 236-249, 2020 | 378 | 2020 |
| Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells AK Pathak, M Bhutani, AS Nair, KS Ahn, A Chakraborty, H Kadara, ... Molecular cancer research 5 (9), 943-955, 2007 | 305 | 2007 |
| IL6 blockade reprograms the lung tumor microenvironment to limit the development and progression of K-ras–mutant lung cancer MS Caetano, H Zhang, AM Cumpian, L Gong, N Unver, EJ Ostrin, S Daliri, ... Cancer research 76 (11), 3189-3199, 2016 | 195 | 2016 |
| Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up H Kadara, M Choi, J Zhang, ER Parra, J Rodriguez-Canales, SG Gaffney, ... Annals of Oncology 28 (1), 75-82, 2017 | 194 | 2017 |
| Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma T Cascone, MH Herynk, L Xu, Z Du, H Kadara, MB Nilsson, CJ Oborn, ... The Journal of clinical investigation 121 (4), 1313-1328, 2011 | 178 | 2011 |
| Comprehensive T cell repertoire characterization of non-small cell lung cancer A Reuben, J Zhang, SH Chiou, RM Gittelman, J Li, WC Lee, J Fujimoto, ... Nature communications 11 (1), 603, 2020 | 168 | 2020 |
| Ets2 mediated tumor suppressive function and met oncogene inhibition in human non–small cell lung cancer M Kabbout, MM Garcia, J Fujimoto, DD Liu, D Woods, CW Chow, ... Clinical cancer research 19 (13), 3383-3395, 2013 | 165 | 2013 |
| Circulating tumor cell detection technologies and clinical utility: Challenges and opportunities Z Habli, W AlChamaa, R Saab, H Kadara, ML Khraiche Cancers 12 (7), 1930, 2020 | 163 | 2020 |
| EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non–small cell lung carcinoma C Behrens, LM Solis, H Lin, P Yuan, X Tang, H Kadara, E Riquelme, ... Clinical cancer research 19 (23), 6556-6565, 2013 | 154 | 2013 |
| High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and mutation MI Nunez, C Behrens, DM Woods, H Lin, M Suraokar, H Kadara, ... Journal of thoracic oncology 7 (5), 833-840, 2012 | 151 | 2012 |
| Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung P Yuan, H Kadara, C Behrens, X Tang, D Woods, LM Solis, J Huang, ... PloS one 5 (2), e9112, 2010 | 144 | 2010 |
| Image analysis–based assessment of PD-L1 and tumor-associated immune cells density supports distinct intratumoral microenvironment groups in non–small cell lung carcinoma patients ER Parra, C Behrens, J Rodriguez-Canales, H Lin, B Mino, J Blando, ... Clinical Cancer Research 22 (24), 6278-6289, 2016 | 143 | 2016 |
| Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov … F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ... External Resources Crossref (DOI), 2012 | 143 | 2012 |
| Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome LM Solis, C Behrens, MG Raso, HY Lin, H Kadara, P Yuan, H Galindo, ... Cancer 118 (11), 2889-2899, 2012 | 128 | 2012 |
| Pulmonary adenocarcinoma: a renewed entity in 2011 H Kadara, M Kabbout, II Wistuba Respirology 17 (1), 50-65, 2012 | 111 | 2012 |
| Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer Y Kudo, C Haymaker, J Zhang, A Reuben, DY Duose, J Fujimoto, ... Annals of Oncology 30 (9), 1521-1530, 2019 | 107 | 2019 |
| Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma X Hu, J Fujimoto, L Ying, J Fukuoka, K Ashizawa, W Sun, A Reuben, ... Nature communications 10 (1), 2978, 2019 | 104 | 2019 |
| Early events in the molecular pathogenesis of lung cancer H Kadara, P Scheet, II Wistuba, AE Spira Cancer prevention research 9 (7), 518-527, 2016 | 103 | 2016 |
